|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: WDR36 |
Gene summary for WDR36 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | WDR36 | Gene ID | 134430 |
| Gene name | WD repeat domain 36 | |
| Gene Alias | GLC1G | |
| Cytomap | 5q22.1 | |
| Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | Q8NI36 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 134430 | WDR36 | LZE4T | Human | Esophagus | ESCC | 1.28e-07 | 5.17e-02 | 0.0811 |
| 134430 | WDR36 | LZE7T | Human | Esophagus | ESCC | 6.68e-06 | 1.50e-01 | 0.0667 |
| 134430 | WDR36 | LZE8T | Human | Esophagus | ESCC | 1.76e-07 | 3.85e-02 | 0.067 |
| 134430 | WDR36 | LZE20T | Human | Esophagus | ESCC | 9.77e-04 | 6.79e-02 | 0.0662 |
| 134430 | WDR36 | LZE24T | Human | Esophagus | ESCC | 4.77e-15 | 1.91e-01 | 0.0596 |
| 134430 | WDR36 | LZE6T | Human | Esophagus | ESCC | 4.76e-02 | 5.31e-02 | 0.0845 |
| 134430 | WDR36 | P1T-E | Human | Esophagus | ESCC | 3.70e-02 | 1.27e-01 | 0.0875 |
| 134430 | WDR36 | P2T-E | Human | Esophagus | ESCC | 5.86e-20 | 2.67e-01 | 0.1177 |
| 134430 | WDR36 | P4T-E | Human | Esophagus | ESCC | 1.44e-06 | 1.34e-01 | 0.1323 |
| 134430 | WDR36 | P5T-E | Human | Esophagus | ESCC | 2.41e-15 | 8.62e-02 | 0.1327 |
| 134430 | WDR36 | P8T-E | Human | Esophagus | ESCC | 3.16e-10 | 7.70e-02 | 0.0889 |
| 134430 | WDR36 | P9T-E | Human | Esophagus | ESCC | 5.58e-09 | 7.68e-02 | 0.1131 |
| 134430 | WDR36 | P10T-E | Human | Esophagus | ESCC | 3.48e-14 | 1.44e-01 | 0.116 |
| 134430 | WDR36 | P11T-E | Human | Esophagus | ESCC | 2.62e-13 | 2.25e-01 | 0.1426 |
| 134430 | WDR36 | P12T-E | Human | Esophagus | ESCC | 3.88e-15 | 2.90e-01 | 0.1122 |
| 134430 | WDR36 | P15T-E | Human | Esophagus | ESCC | 1.29e-23 | 4.53e-01 | 0.1149 |
| 134430 | WDR36 | P16T-E | Human | Esophagus | ESCC | 1.75e-16 | 5.27e-02 | 0.1153 |
| 134430 | WDR36 | P17T-E | Human | Esophagus | ESCC | 8.24e-04 | 2.64e-01 | 0.1278 |
| 134430 | WDR36 | P19T-E | Human | Esophagus | ESCC | 1.79e-05 | 3.40e-01 | 0.1662 |
| 134430 | WDR36 | P20T-E | Human | Esophagus | ESCC | 4.06e-28 | 5.63e-01 | 0.1124 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0022613111 | Esophagus | ESCC | ribonucleoprotein complex biogenesis | 365/8552 | 463/18723 | 1.74e-49 | 1.11e-45 | 365 |
| GO:0042254111 | Esophagus | ESCC | ribosome biogenesis | 252/8552 | 299/18723 | 3.27e-44 | 1.04e-40 | 252 |
| GO:003447015 | Esophagus | ESCC | ncRNA processing | 300/8552 | 395/18723 | 3.09e-35 | 3.26e-32 | 300 |
| GO:0016072110 | Esophagus | ESCC | rRNA metabolic process | 197/8552 | 236/18723 | 1.31e-33 | 1.18e-30 | 197 |
| GO:0006364110 | Esophagus | ESCC | rRNA processing | 189/8552 | 225/18723 | 4.88e-33 | 3.87e-30 | 189 |
| GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
| GO:002261322 | Liver | HCC | ribonucleoprotein complex biogenesis | 355/7958 | 463/18723 | 7.76e-52 | 4.92e-48 | 355 |
| GO:004225422 | Liver | HCC | ribosome biogenesis | 246/7958 | 299/18723 | 4.99e-46 | 1.58e-42 | 246 |
| GO:00344702 | Liver | HCC | ncRNA processing | 293/7958 | 395/18723 | 4.26e-38 | 6.76e-35 | 293 |
| GO:001607212 | Liver | HCC | rRNA metabolic process | 193/7958 | 236/18723 | 1.26e-35 | 1.14e-32 | 193 |
| GO:000636421 | Liver | HCC | rRNA processing | 185/7958 | 225/18723 | 8.14e-35 | 6.45e-32 | 185 |
| GO:00346601 | Liver | HCC | ncRNA metabolic process | 332/7958 | 485/18723 | 1.48e-31 | 7.80e-29 | 332 |
| GO:002261320 | Oral cavity | OSCC | ribonucleoprotein complex biogenesis | 333/7305 | 463/18723 | 8.28e-48 | 5.24e-44 | 333 |
| GO:004225420 | Oral cavity | OSCC | ribosome biogenesis | 230/7305 | 299/18723 | 3.22e-41 | 6.80e-38 | 230 |
| GO:000636410 | Oral cavity | OSCC | rRNA processing | 172/7305 | 225/18723 | 1.57e-30 | 1.24e-27 | 172 |
| GO:00344709 | Oral cavity | OSCC | ncRNA processing | 263/7305 | 395/18723 | 4.38e-29 | 2.78e-26 | 263 |
| GO:001607210 | Oral cavity | OSCC | rRNA metabolic process | 176/7305 | 236/18723 | 6.51e-29 | 3.24e-26 | 176 |
| GO:00346605 | Oral cavity | OSCC | ncRNA metabolic process | 296/7305 | 485/18723 | 2.94e-23 | 6.65e-21 | 296 |
| GO:002261329 | Skin | cSCC | ribonucleoprotein complex biogenesis | 302/4864 | 463/18723 | 5.13e-72 | 3.22e-68 | 302 |
| GO:004225428 | Skin | cSCC | ribosome biogenesis | 206/4864 | 299/18723 | 3.33e-55 | 1.04e-51 | 206 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| WDR36 | SNV | Missense_Mutation | c.1606N>G | p.Gln536Glu | p.Q536E | Q8NI36 | protein_coding | tolerated(0.36) | benign(0.006) | TCGA-A8-A08R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| WDR36 | SNV | Missense_Mutation | rs752635516 | c.68T>G | p.Leu23Arg | p.L23R | Q8NI36 | protein_coding | tolerated_low_confidence(0.41) | benign(0) | TCGA-BH-A8FZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| WDR36 | SNV | Missense_Mutation | c.2068N>G | p.Leu690Val | p.L690V | Q8NI36 | protein_coding | deleterious(0) | possibly_damaging(0.723) | TCGA-EW-A1J5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| WDR36 | deletion | Frame_Shift_Del | novel | c.1817delN | p.Leu607TrpfsTer3 | p.L607Wfs*3 | Q8NI36 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| WDR36 | SNV | Missense_Mutation | novel | c.2637N>T | p.Met879Ile | p.M879I | Q8NI36 | protein_coding | tolerated(0.07) | possibly_damaging(0.796) | TCGA-DG-A2KJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| WDR36 | SNV | Missense_Mutation | c.1087G>C | p.Asp363His | p.D363H | Q8NI36 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EK-A2PL-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
| WDR36 | SNV | Missense_Mutation | c.1351N>A | p.Glu451Lys | p.E451K | Q8NI36 | protein_coding | tolerated(0.39) | benign(0.024) | TCGA-EK-A2RA-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| WDR36 | SNV | Missense_Mutation | c.42G>T | p.Gln14His | p.Q14H | Q8NI36 | protein_coding | tolerated_low_confidence(0.12) | benign(0) | TCGA-AA-3530-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| WDR36 | SNV | Missense_Mutation | novel | c.1636N>A | p.Ala546Thr | p.A546T | Q8NI36 | protein_coding | tolerated(0.1) | probably_damaging(0.927) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| WDR36 | SNV | Missense_Mutation | c.811G>T | p.Val271Phe | p.V271F | Q8NI36 | protein_coding | deleterious(0) | benign(0.167) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |